FDA publishes updated CAR T regulatory framework

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA published a perspective article in JAMA that describes the agency’s current regulatory thinking for the development of CAR T-cell therapies. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

In 1971, the National Cancer Act set the United States on a path to confront one of its most formidable public health challenges. More than five decades later, the progress is undeniable. The latest 2026 report from the American Cancer Society shows continued declines in overall cancer mortality and improvements in survival for many major cancer types. Recent advances in early detection, prevention, and treatment are saving lives.
Jacquelyn Cobb
Associate Editor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login